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Background: Neutron capture therapy for glioblastoma has focused mainly on the use of 10B as neutron capture
isotope. However, 157Gd offers several advantages over boron, such as higher cross section for thermal neutrons and
the possibility to perform magnetic resonance imaging during neutron irradiation, thereby combining therapy and
diagnostics. We have developed different liposomal formulations of gadolinium-DTPA (Magnevist®) for application in
neutron capture therapy of glioblastoma. The formulations were characterized physicochemically and tested in vitro in
a glioma cell model for their effectiveness.
Methods: Liposomes entrapping gadolinium-DTPA as neutron capture agent were manufactured via lipid/film-extrusion
method and characterized with regard to size, entrapment efficiency and in vitro release. For neutron irradiation, F98 and
LN229 glioma cells were incubated with the newly developed liposomes and subsequently irradiated at the thermal
column of the TRIGA reactor in Mainz. The dose rate derived from neutron irradiation with 157Gd as neutron capturing
agent was calculated via Monte Carlo simulations and set in relation to the respective cell survival.
Results: The liposomal Gd-DTPA reduced cell survival of F98 and LN229 cells significantly. Differences in liposomal
composition of the formulations led to distinctly different outcome in cell survival. The amount of cellular Gd was not at
all times proportional to cell survival, indicating that intracellular deposition of formulated Gd has a major influence on cell
survival. The majority of the dose contribution arises from photon cross irradiation compared to a very small Gd-related
dose.
Conclusions: Liposomal gadolinium formulations represent a promising approach for neutron capture therapy of
glioblastoma cells. The liposome composition determines the uptake and the survival of cells following radiation,
presumably due to different uptake pathways of liposomes and intracellular deposition of gadolinium-DTPA. Due to
the small range of the Auger and conversion electrons produced in 157Gd capture, the proximity of Gd-atoms to cellular
DNA is a crucial factor for infliction of lethal damage. Furthermore, Gd-containing liposomes may be used as MRI
contrast agents for diagnostic purposes and surveillance of tumor targeting, thus enabling a theranostic approach for
tumor therapy.
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Neutron capture therapy (NCT) is a cancer treatment
approach based on accumulation of neutron capture
agent at the tumor site and irradiation of the tumor with
thermal neutrons as a second step. In the past, research
has focused primarily on 10B as neutron capture agent.
However, 157Gd may be an alternative element for NCT
[1]. Gadolinium provides several advantages over boron,
namely the highest cross section for thermal neutrons
known for stable elements (157Gd: 255,000 barn) and fol-
lowing administration, the possibility to trace the agent
through the body via magnetic resonance imaging
(MRI), thereby allowing a theranostic approach to can-
cer treatment [2]. The fission products of 10B, an alpha
particle and recoiling Li-nucleus, have path lengths of
approximately 9–12 μm, i.e. the range of an individual
cell. In contrast, neutron capture reaction of 157Gd re-
sults in the generation of 158Gd, at least five Auger- and
inner conversion electrons and photons of different en-
ergies. Auger- and inner conversion electrons are
thought to be the main contributors to the cell killing ef-
fect of Gd-NCT. It was shown by Martin and co-authors
1989 [3] that the Auger electrons from Gd-neutron cap-
ture reaction led to DNA double-strand breaks and sub-
sequent cell death. Since path lengths for Auger and
inner conversion electrons are extremely short (nm to
lower μm range), intracellular accumulation and distri-
bution of Gd is very important for the radiation effect.
To reach the main target for radiation therapy in cells,
the DNA, the Gd-atom has to be located in close prox-
imity to the cellular nucleus. In addition to the short-
ranged Auger and inner conversion electrons, the 157Gd
neutron capture reaction produces long-range gamma
rays of different energies up to 8 MeV whose flight
ranges are not limited to a single cell. Similar to pho-
ton radiation therapy, these gamma rays may also
interact with cellular structures if gadolinium was
located outside the target cells, thus inflicting DNA le-
sions, however to a much smaller extent. Furthermore,
an additional dose may be produced by self-absorption
of the gamma rays by the gadolinium load at the tumor
site, thus generating further Auger electrons via photo-
electric effect.
A crucial point in gadolinium neutron capture therapy
is the provision and retention of high gadolinium con-
centration in the target tissue. Shih and Brugger 1992
[4] calculated that 50–200 μg 157Gd/g wet tumor tissue
should be sufficient for successful cancer treatment. The
administration of liposomes as drug carrier systems of-
fers several advantages over the free drug, such as the
shielding of entrapped drugs from degradation and tar-
geting the drug carrier exclusively to the tumor site by
addition of cell-specific targeting structures. Further-
more, the uptake of liposomes may supersede the uptakeof free drug due to higher payload of the carrier and by
taking advantage of different uptake mechanisms.
In the present study, we introduce several novel Gd-
containing liposomal formulations for application in
neutron capture therapy. Composite liposomes employ-
ing different lipids were designed in order to facilitate
uptake into cancer cells and to deliver sufficient
amounts of Gd into the target cell. Lipids were chosen
according to their physicochemical and biogenic charac-
teristics or estimated uptake properties, e.g. anionic Car-
diolipin, a component of mitochondrial membrane
which is involved in the mitochondria-dependent apop-
tosis [5] and fusogenic DOPE, known for the ability to
escape endosomal compartments after uptake through
conformational change [6-8]. Cationic DOTAP ensures
electrostatic attraction between cellular membranes and
liposomes, thus facilitating binding as the first step in
the liposomal drug uptake process [9,10]. As a specified
targeting structure, folate, a substrate for folate receptor
alpha, which is overexpressed in many tumor types, was
selected. While reduced folate carrier (RFC) is ubiqui-
tous, FR alpha (FR α) is rarely expressed in normal tis-
sues, but known for its overexpression in tumor tissues,
amongst other in breast and ovarian cancer, melanoma
and brain tumors such as glioma [11-15].
The specific aim of this study encompasses an evalu-
ation of the suitability of Magnevist-entrapping compos-
ite liposomes as nanocarrier system for Gd-NCT of
glioma cells. Liposomes were characterized physico-
chemically and according to their toxicity and uptake
into F98 (rat glioma) and LN229 (human glioblastoma)
cells. Performance of the drug carrier system for neutron
capture agents was investigated in a glioma cell model
regarding drug uptake and cell survival subsequent to ir-
radiation with thermal neutrons. Cell survival was then
related to Gd-concentration in cells. Simultaneously,
Monte Carlo simulations of the mixed neutron-gamma
field and the resulting dose on the 96 well plates in the
medium and on the cellular level were performed to as-




Liposomes were prepared according to the lipid film-
extrusion method. Lipids were purchased from Avanti
Polar Lipids, Alabaster, AL, USA (folate-PEG2000-
DSPE), Sigma Aldrich Co., St. Louis, MO, USA (DOPC,
cholesterol, Cardiolipin) or were a gift from Lipoid GmbH,
Ludwigshafen, Germany (DOPE, DOTAP). Lipid mixtures
consisted of (mol %): DOPC: cholesterol: DOPE (70:20:10),
DOPC: cholesterol: Cardiolipin (70:20:10), DOPC: choles-
terol: DOTAP (57.41:33.35:9.23), DOPC: cholesterol:
folate-PEG2000-DSPE (63.19:36.67:0.13), DOPC: DOPE
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chloroform was dried under vacuum on a rotary evapor-
ator to form a thin lipid film. Subsequently, the film was
rehydrated with Magnevist® solution (Bayer Vital GmbH,
Leverkusen, Germany) or PBS (Life Technologies GmbH,
Darmstadt, Germany) to obtain a lipid concentration of
40 mg/ml. The mixture was vortexed thoroughly and sub-
jected to five freeze-thaw cycles, i.e. the dispersion was fro-
zen in liquid nitrogen for one minute and thawed in a
water bath of 37°C for five to six minutes. The resulting
lipid dispersion was extruded eleven times through a
100 nm polycarbonate membrane using an Avanti Mini
Extruder® (Avanti Polar Lipids, Alabaster, AL, USA). Non-
entrapped material was removed via minicolumn centrifu-
gation/gel permeation chromatography method (GPC)
with Sephadex™ G-25 Medium (GE Healthcare, Uppsala,
Sweden) as column material.
Liposome characterization
Size measurements were performed via dynamic light
scattering with Zetasizer Nano ZS (Malvern Technolo-
gies, Herrenberg, Germany) at 173° scattering angle.
Liposome dispersions were diluted with PBS to yield a
lipid concentration of 0.25 mg/ml. Determination of zeta
potential was carried out with the same instrument, with
liposomes suspended in double-distilled water at a lipid
concentration of 0.25 mg/ml.
Entrapment efficiency was determined via mass-
spectrometric analysis of Gd-content in liposome disper-
sions after GPC in regard to total Gd-amount of the
liposome dispersion before GPC treatment.
In vitro release experiments
Release of Magnevist from liposomes was tested for
DOPC-DOPE and DOTAP-liposomes via flow-through dis-
solution in a Sotax CE 7 apparatus with liposome adapter
devices (Sotax AG, Allschwill, Switzerland). Adapters were
used with a cellulose ester dialysis membrane MWCO 3.5
to 5 kD (Spectrum Laboratories, Rancho Dominguez, CA,
USA). 450 μl of liposome dispersion or diluted Magnevist
solution were pipetted into adapters and placed into a
22.6 mm tablet flow-through cell. To ensure laminar flow,
glass beads were filled into the base of each dissolution cell.
Dissolution medium consisted of 50 ml PBS in a closed cir-
culation, with a pump rate of 16 ml/min. Dissolution was
performed for 3 h at 37°C. Samples of 1 ml volume were
extracted at defined time points and replenished with fresh




F98 rat glioma cell line and LN229 human glioblastoma
cell line were purchased from LGC/American TypeCulture Collection, Middlesex, UK. Two days prior to
radiation experiments, cells were seeded into 96 well
plates at a density of 4000 cells per well. Medium was
exchanged against fresh growth medium supplemented
with liposomal formulations at concentrations of 0.27 to
0.47 mg Gd/ml or Magnevist solution three hours prior
to neutron irradiation. Cell culture plates were then
sealed with adhesive tape to prevent loss of CO2, trans-
ported to TRIGA Mark II reactor and always stacked in
the same order into a polyethylene irradiation box. Neu-
tron irradiation was carried out at room temperature
with neutron fluences of about 2.4 to 2.7 · 1012 particles
per cm2 and photon fluences of about 6.3 · 1011 to 7.2 ·
1011 particles/cm2 corresponding to 15 min irradiation
with 20 kW reactor power and about 3.6 to 4.05 · 1012
particles/cm2 and photon fluences of about 9.45 to
10.8 · 1011 particles/cm2 corresponding to 22.5 min ir-
radiation with 20 kW reactor power, respectively, at the
central irradiation chamber of the thermal column. After
irradiation and a cooling down period of approximately
45 min, the activated medium containing liposomes or
Magnevist® was aspirated off and replenished with fresh
growth medium. Cells were kept under recommended
growth conditions, until MTT proliferation assay was
performed.Uptake experiments
For uptake experiments, cells were seeded into 100 mm
petri dishes at densities of 1.4 · 106 and 1.6 · 106 cells for
F98 and LN229 cells, respectively. After two days under
recommended growth conditions, medium was changed
and cells were incubated with liposomal formulations or
Magnevist solution for 1 to 24 hours. Cells were then
washed thoroughly with ice-cold PBS, harvested and
counted for mass spectrometric analysis of Gd-content.MTT proliferation assay
MTT (3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyl-2H-tet-
razoliumbromide, Carl Roth GmbH & Co. KG, Karls-
ruhe, Germany) cell proliferation assays were performed
97 h after cell irradiation experiments to estimate cell
survival. Cell growth medium was aspirated off, replaced
with 100 μl of 0.5 g/l MTT solution and incubated for
30 min. In the next step, MTT working solution was re-
moved and exchanged against 180 μl dimethyl sulfoxide
(Carl Roth GmbH & Co. KG, Karlsruhe, Germany)
which were also left to incubation for 30 min at 37° to
ensure complete dissolving of the formazan crystals. The
resulting blue colored extract was pipetted into a fresh mi-
croplate for the read-out in a Tecan infinite™ F200 plate
reader (Tecan Group Ltd., Männedorf, Switzerland) at ab-
sorption wavelength 560 nm and reference wavelength
690 nm.
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lows: cells were incubated with liposomal formulations
or Magnevist for three hours in parallel to irradiation
experiments. These cells were treated in the same way
as irradiated cells, i.e. concerning incubation time with
liposomal formulations, transport to the TRIGA reactor
and medium exchange, except for the neutron irradi-
ation. Repetitive MTT tests were then performed every
24 hours for three days. Results are arithmetic means ±
SD of all three assays, based on untreated control cells
in growth medium.
Analysis of cellular Gd-content
Gd-content in liposome- or Magnevist®-treated cells was
determined via inductively coupled plasma mass spec-
trometry. Briefly, cells harvested from uptake experi-
ments were digested with hydrogen peroxide/nitric acid
mixture and diluted with double distilled water. After
addition of 10 ppm Eu as internal standard, the solution
was analyzed on an Agilent ICP-MS 7500 ce (Agilent
Technologies, Santa Clara, CA, USA), using a concentric
0.05 ml/min nebulizer and a cyclone spray chamber.
Rinsing between samples was done with solutions con-
sisting of i) (1.25% w/w) HNO3 and ii) (1.25% w/w) ni-
tric acid. All chemicals were purchased from Carl Roth
GmbH and Co. KG, Karlsruhe, Germany and were of
analytical grade or higher.
Monte Carlo simulations
The neutron and photon dose during irradiation exper-
iments were calculated using MCNP 5 program (Los
Alamos National Security, Los Alamos, New Mexiko,
USA). The neutron field was simulated with a defined
source plane at the front of the thermal column. The
agreement of the model with the real conditions at
TRIGA reactor had been confirmed before [16,17]. The
geometry of the well plates was incorporated into the
MCNP model alongside with the gadolinium concen-
tration of the different wells which was taken from the
analysis mentioned in the previous paragraphs. The
natural abundance of gadolinium isotopes was used as
isotopic composition. In the simulations, the optional
libraries rmccsa and misc5xs were used in order toTable 1 Size, zeta potential and entrapment efficiency for Ma
Formulation (mol%) Diameter [nm] ± SD Zeta po
[mV] ±
DOPC-Chol-DOTAP (57:33:9) 136.20 ± 8.07 41.25 ±
DOPC-Chol-CL (70:20:10) 152.11 ± 10.22 −67.77 ±
DOPC-Chol-DOPE (70:20:10) 133.19 ± 5.76 −15.53 ±
DOPC-Chol-FolPEG 2000 (63:37:0.13) 136.77 ± 8.81 −24.70 ±
DOPC-DOPE (50:50) 138.54 ± 10.17 −17.78 ±account for the gamma production following the neu-
tron capture by gadolinium. Different MCNP transpor-
tation modes were applied such as n (neutron tracking
only, local dose deposition of others), np (neutron and
photon tracking, local dose deposition of others) and
npe (neutron, photon and electron) tracking. Different
MCNP tallies were set and for comparison also the
Kerma approximation was applied where the entire en-
ergy released in a nuclear reaction is deposited locally,




Liposomal formulations of Magnevist showed narrow
size distributions with mean particle sizes of approxi-
mately 136 to 152 nm. The introduction of charged or
functionalized lipids did not affect liposome size signifi-
cantly as shown in Table 1. As expected, zeta potential
measurements revealed high influence of charged lipids
in the lipid mixture, leading to high positive zeta poten-
tial of DOTAP-containing liposomes and high negative
zeta potential of Cardiolipin-containing liposomes. En-
trapment efficiencies of the Gd-chelate complex were
comparable for all tested liposome compositions (9.4 to
10.2%) except for the slightly lower entrapment in
Cardiolipin-containing formulation (6.6%). Concentra-
tion of gadolinium in the final liposome suspension was
therefore 3.3 to 5.9 mg/ml, respective Gd-concentrations
per well for irradiation experiments are given in Table 1.
Toxicity of Magnevist and liposomal Magnevist
formulations
Determination of cytotoxic effects of liposomal and free
Magnevist was performed via MTT assay in parallel to ir-
radiation experiments. As shown in Figure 1, Magnevist
and liposomal formulations thereof showed no relevant
toxicity for both cell lines. Except for cationic DOTAP-
formulation with 12% decrease in cell survival of F98 cells,
all liposomal preparations lead to less than 10% decrease
in cell viability for both F98 and LN229 cells. The higher
toxicity for the cationic formulation is probably caused by
the presence of the cationic charge on the liposomegnevist in liposomal formulations
tential
SD
Encapsulation efficiency [%] Gd concentration per
well [mg/ml]
2.49 10.24 ± 4.85 0.47
2.70 6.56 ± 1.74 0.27
7.53 9.37 ± 2.83 0.36
3.10 9.60 ± 1.75 0.36
6.04 10.21 ± 2.53 0.46
Figure 1 Toxicity of Magnevist and Magnevist containing
liposomal formulations. Cells were incubated for three hours with
respective liposomal Magnevist solution at lipid concentration of 4
mg/ml or with Magnevist solution. Gd-concentration of Magnevist
solution was 0.34 mg/ml for ‘Magnevist’ and 0.68 mg/ml for ‘Magnevist
2’. Table 1 lists respective concentrations in wells. Cells of the control
group were left in complete growth medium without supplement of
liposomes or Magnevist. MTT assays were performed every 24 hours for
three days subsequent to treatment. Results are arithmetic means of the
three assays, based on medium control group, error bars represent SD.
Figure 2 In vitro release of gadolinium-DTPA from liposomal
formulations. Percent release of Magnevist from DOTAP- and
DOPC-DOPE-liposomes. Magnevist solution alone was used as a
control. Dissolution was performed for three hours at 37°C in a flow-
through cell equipped with liposome adapters and in closed
circulation. Results are arithmetic means, error bars represent SD, n = 3.
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polymers bring about a certain cell toxicity due to the
charge they carry and to their subsequent interaction
with essential cellular enzymes. However, since in our
case the cytotoxicity of cationic liposomes was only
moderately higher than for neutral and negatively
charged formulations (12% in contrast to 10%), this as-
pect was considered as negligible.
In vitro release of Gd from liposomal formulations
Release profiles (Figure 2) show an initial burst of
gadolinium-DTPA from liposomal formulations in the
first five minutes of the dissolution experiment. Since
free Magnevist also shows this stage, the fast release ap-
parently attributes to already liberated gadolinium-DTPA diffusing out from the dissolution bag. In the sec-
ond stage, release is also relatively fast, until the amount
of liberated Gd-compound asymptotically approaches a
maximum after 3 hours. At this time point, the
remaining gadolinium-DTPA trapped inside the lipo-
somes is approximately 3% for DOPC-DOPE-liposomes
and more than 20% for DOTAP-liposomes. After one
hour, approximately 50% of the neutron capture agent is
still safely entrapped in liposomal formulations. Lipo-
somes show therefore a sufficiently high retention of
gadolinium-DTPA for at least one hour at 37°C. Never-
theless, a three-hour time span was set as incubation
period to ensure sufficient opportunity for cellular
uptake.
Uptake of Gd-DTPA into cells
Free Magnevist was taken up into glioma cells in a
time- and concentration-dependent manner. As shown
in Figure 3, uptake into F98 and LN229 cells was nearly
linearly proportional to exposure times and concentra-
tion of gadolinium in the culture medium. DOPC-
DOPE liposomes showed similar behavior, but overall
uptake of the liposomal Magnevist formulation after
3 hours was 1.3 and 3 fold higher than that of free Magne-
vist for F98 and LN229 cells, respectively (Figure 4). Both
cell lines took up cationic DOTAP-liposomes to the high-
est extent with 1921 ng Gd/106 cells in F98 cells and
2481 ng Gd/106 cells in LN229 cells after a 3 hour incuba-
tion period (Figure 5). Uptake of DOTAP-liposomes was
therefore significantly higher than uptake of all other for-
mulations, with p < 0.001 (one-way ANOVA and subse-
quent Tukey’s multiple comparison test, where six groups
were compared separately for each cell line. LN229: R2 =
0.9199, 5 degrees of freedom, residual sum of squares:
1342000, degrees of freedom 21; F98: R2 = 0.9108, 5 de-
grees of freedom, residual sum of squares: 901300, 19
Figure 3 Time- and concentration dependent uptake of free
Magnevist into F98 and LN229 cells. (A) LN229 and F98 glioma
cells were incubated with Magnevist solution (0.34 mg/ml) for time
periods of 1 to 24 h. (B) F98 cells were incubated with different
concentrations of Magnevist solution (0.18 to 0.9 mg/ml) for 24 and
48 h, respectively. Resulting Gd-concentration in the cells was
determined via ICP-MS, n = 3.
Figure 4 Time-dependent uptake of liposomal gadolinium
formulations (DOTAP and DOPC-DOPE) and Magnevist into F98
cells. Gd-concentration in (A) F98 and (B) LN229 cells after incubation
with liposomal Magenvist formulations, i.e. DOPC-DOPE and DOTAP
(1 mg lipid/ml, respective Gd-concentration cf. Table 1) and Magnevist
(0.34 mg Gd/ml) for 1 to 24 h. Gd-concentration was determined via
ICP-MS. Results are arithmetic means, error bars represent SD, n = 3.
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showed a different uptake kinetic than DOPC-DOPE and
Magnevist formulations in both cell lines. As presented in
Figure 4, uptake of DOTAP-liposomes reached a max-
imum after three hours and declined afterwards, while the
other two formulations approached a plateau after
24 hours incubation time.
Furthermore, results from uptake experiments clearly
show great variances in liposome uptake according to
lipid composition and in part, dependency on the cell
line. DOPE- and anionic Cardiolipin-liposomes trans-
ported comparable amounts of gadolinium into LN229
cells, but for F98 cells, DOPE-liposomes delivered nearly
twice as much gadolinium as Cardiolipin-liposomes.Cell irradiation experiments
Irradiation of glioma cell lines as described above led to
a decreased total cell survival of 84 and 77% for F98,
and 83 and 81% for LN229 cells, respectively. Treatmentwith ‘free’ Magnevist solution led to further decrease of
survival, approximately 13% (F98 cells) and 7–10%
(LN229 cells) below survival of non-irradiated control
cells. Higher concentration of free Magnevist solution
(Magnevist 2, cf. Figure 6) was beneficial in case of F98
cells with lower fluence, where the total survival receded
to 63%. However, for higher fluence and for LN229 cells,
the increased concentration of Magnevist did not im-
prove the effect under radiation.
Application of liposomal Magnevist formulations, on
the other hand, had highest effect on cell survival of
both F98 and LN229 cells. While DOPE- and CL-
formulations showed relatively small effect on cell sur-
vival, their application on F98 cells produced better
results compared to free Magnevist under the same ir-
radiation conditions. For LN229 cells, the outcome after
treatment with DOPE- and CL-liposomes was slightly
below expectations with approximately 80 and 74% sur-
vival. Nevertheless, folate -, DOPC-DOPE- and DOTAP-
liposomes led to significantly lower cell survival than
Figure 5 Uptake of liposomal gadolinium-formulations and
Magnevist into (right) F98 and (left) LN229 cells. Gd-concentration
(logarithmic scale) in LN229 and F98 cells after 3 h incubation with
liposomal Magnevist formulations (lipid concentration 1 mg/ml,
respective Gd-concentration cf. Table 1) and free Magnevist
(0.34 mg Gd/ml). Gd-concentration was determined via ICP-MS.
Results are arithmetic means of at least three experiments, error bars
represent SD. *** p < 0.001, ANOVA, Tukey’s multiple comparison.
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subsequent Tukey’s multiple comparison test, where flu-
ence was included as a factor, p < 0.01 (Folate - and
DOTAP-liposomes), p < 0.05 DOPC-DOPE-liposomes,
comparison of 14 groups, including drug-free liposomes
of the different lipid compositions, degrees of freedom:
13, R2 = 0.9046). For F98 cells, significantly better effects
compared to medium control were observed after treat-
ment with DOTAP- and DOPC-DOPE-liposomes (one-
way ANOVA, subsequent Tukey’s multiple comparison
test, p < 0.01, only fluence of 3.6 to 4.05 · 1012 n/cm2,
comparison of 14 groups, including drug-free liposomes
of the different lipid compositions, degrees of freedom:
13, R2 = 0.4659). The residual sum of squares for the
analysis of LN229 was 137.7, with 14 degrees offreedom. For F98, the residual sum of squares was 9241,
with 44 degrees of freedom.
Correlation between Gd-content and respective cell
survival
Gadolinium content in cells is a major factor for the
overall dose and the subsequent effect on cell survival
under neutron irradiation. Therefore, Monte Carlo sim-
ulations including the Gd amount per well were used to
determine neutron and photon dose. Figure 7 presents
the neutron and photon dose rate per minute on single-
well level for irradiation of LN229 cells. In this context
the term neutron dose represents all dose components
arising from neutron interaction, i.e. local energy depos-
ition from Auger and conversion electrons as well as the
14 N (n,p) 14C reaction from the nitrogen present. The
diagram shows that the bigger part of the dose derives
from photons generated in neutron capture events as
well as photons produced in the environment of the
thermal column of the radiation site. The contribution of
photon self-irradiation, i.e. the dose inflicted from photons
that origininate from the same well is only in the order of
the natural background radiation. The dose ascribed to
neutrons alone only accounts for roughly 5–10% of the
overall dose (sum of neutron and photon dose). Conse-
quently it can be said that the majority of the dose contri-
bution arises from photon cross irradiation which is why
the KERMA-approximation is not valid for simulation of
dose arising from neutron capture of 157Gd.
In the next step, cell survival and Gd-related dose on
single-well level were correlated. Subtraction of simu-
lated dose in control wells containing only medium
without drug from gadolinium-containing wells resulted
in Gd-related dose (both neutrons and photons gener-
ated by Gd-neutron capture event) which accounted for
13 to 32% of overall dose, i.e. 0.6 to 2.8 Gy, depending
on Gd-content of the well (Figure 8). In this case, the
entire amount of Gd per well is included in the calcula-
tion, irrespective of its location towards the cell, i.e. in-
side, after being taken up, or outside in the medium. By
this means, dose from long-range gamma rays (Gd lo-
cated outside the cell) and dose from Auger- and inner
conversion electrons (Gd located inside the cell) after
neutron capture reaction of 157Gd are both accounted
for. However, correlation between the Gd-related dose
regardless of Gd-location and cell survival was poor,
with R2 = 0.46 and a survival decrease of 0.85% per Gy
for F98 cells. Cell survival was also correlated with cellu-
lar Gd-content alone, thus neglecting the Gd concentra-
tion outside the target cells. Here, correlation of cell
survival of F98 cells treated with three different liposo-
mal formulations and free Magnevist with the respective
cellular Gd-content followed an exponential relationship
(R2 = 0.8982, survival decrease of 1%/Gy, for LN229
Figure 6 Survival data of irradiated (A) F98 and (B) LN229 cells, 97 h after irradiation. Cells were treated with liposomal Magnevist
formulations or free Magnevist and incubated for 3 h prior to irradiation with thermal neutrons. Cells of the control group were irradiated, but
contain no drug. MTT assay was performed 97 h after irradiation. Survival is based on a non-irradiated medium control without drug, results are
arithmetic means of three independent experiments, error bars represent SEM. Significant differences in survival compared to control group
(irradiated, medium, no drug) are marked with asterisk, * p < 0.05 and ** p < 0.01 (ANOVA, Tukey’s multiple comparison test).
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only three of five liposomal formulations fit the correl-
ation, while the folate-targeted and the DOPC-DOPE
formulation had to be excluded. For these two formula-
tions, the delivery of gadolinium into the cell was excep-
tionally small in relation to survival of cells, which in
contrast decreased significantly. This anomaly might be
due to different uptake pathways depending on liposome
composition. In case of gadolinium for neutron capture
therapy, the location of the neutron capture agent is
crucial for the effect: the short-ranged Auger andconversion electrons have to reach the DNA strand in
the nucleus to inflict severe lesions and lead to the de-
sired apoptotic cell death [3]. Therefore, different endo-
cytic pathways into the cell may offer a more satisfactory
deposition of Gd inside the cell, i.e. closer to the nu-
cleus. Thus, even small amounts of gadolinium taken up
into the cell may have very high effect on cell survival.
Discussion
Gd-NCT as alternative radiation therapy for high-grade
glioma is a promising tool in cancer treatment. In contrast
Figure 7 Dose rates (neutron, photon and sum of both) on single-well level of a 96 well plate calculated via Monte Carlo simulations.
Dose profile of a 96 well plate, well number 1 to 96 from cold end to hot end of thermal column at TRIGA reactor (left to right). Wells are supplemented
with 4 mg lipid/ml of respective liposomal Magnevist formulations or free Magnevist solution (rows consist of 12 wells, supplemented with the same
formulation). ‘Medium’ wells contain complete growth medium only.
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short-ranged particles, such as Auger- and inner conver-
sion electrons, but also a spectrum of longer-ranged pho-
tons. It is debatable if these photons may indeed
contribute to tumor killing as some authors suggested
[19-21]. According to our simulations and the geometric
dimensions of our experimental set-up, the additional dose
gained by longer-range photons and self-absorption would
be too small, i.e. in the range of natural background radi-
ation. For higher neutron irradiation times, there might be
a beneficial effect, however, for the present study, this was
not the case. Obtaining a sufficient Gd-concentration in
cancer cells is therefore still a key factor in neutron cap-
ture therapy.Figure 8 Gd-related dose versus cell survival of F98 cells.
Correlation of Gd-derived dose (dose rate minus dose rate of control
group without Gd-supplementation) versus cell survival 97 h after
irradiation of F98 cells treated with the respective formulation. Results are
arithmetic means of three experiments, error bars represent
SD (R2 = 0.4671).
Figure 9 Gd-content of (A) F98 and (B) LN229 cells versus cell
survival. Correlation of Gd-concentration in cells after three hour-
incubation with liposomal Magnevist formulation or free Magnevist
versus cell survival 97 h after irradiation of F98 cells with neutron
fluence of 3.6 to 4.05 · 1012 n/cm2 and LN229 cells with neutron fluence
of 2.4 to 2.7 · 1012 n/cm2 treated with respective formulations. Results
are arithmetic means of three experiments, error bars represent SD
(R2 = 0.8982 for F98 cells and R2 = 0.9274 for LN229 cells).
Figure 10 Inactivation of glioma cells via Gd-NCT. Inactivation of
tumor cells (A) F98 cells, (B) LN229 cells, following the equation:
Inactivation = 100% - Total Survival. Neutron fluences were 3.6 to
4.05 · 1012 n/cm2 for F98 cells and 2.4 to 2.7 · 1012 n/cm2 for LN229
cells. Results are arithmetic means of three independent experiments,
error bars represent SEM. Total survival is based on the irradiated
medium control without drug, i.e. the inactivation value shows the
specific effect of the different Gd-formulations. Significance levels
(ANOVA, Tukey’s multiple comparison) are * p < 0.05, ** p < 0.01 and
***p < 0.001, liposomal formulation compared to Magnevist.
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centration in the tumor mass was 50–200 μg/g tumor
[4]. According to Dewi et al. 2013 [19] and others, previ-
ous investigations have shown that high concentrations
of gadolinium are difficult to achieve and retain in tumor
cells with commercially available contrast agents. There-
fore, several approaches have been made to overcome the
difficulty of obtaining effective Gd-concentrations in
tumor mass by application of different particulate drug
carriers, among others Gd-chitosan complexes, lipid
nanoemulsions and gadolinium hexanedione nanoparticles
[22-24]. In the present study, we have shown that varie-
gated composite liposomes are efficient delivery agents for
Gd-compound Magnevist for application in F98 and
LN229 glioma cell lines. DOTAP-liposomes entrapping
Magnevist were able to deliver a nearly threefold higher
amount of Gd into cells than recommended (768 μg Gd/g
F98 cells) and led to a highly significant decrease of cell
survival. However, it has to be pointed out that Magnevist
contains the natural occurring isotope mixture of gadolin-
ium including only 15.7% of 157Gd, resulting in an average
cross section for the mixture of 49 000 barn for thermal
neutrons. Therefore, employment of 157Gd-enriched Gd-
DTPA instead of Magnevist is expected to further enhance
the radiation effect approximately fivefold. Nevertheless,
three out of five Magnevist-containing liposome formula-
tions reduced cell survival significantly, i.e. cationic
DOTAP-, fusogenic DOPC-DOPE and targeted folate-
liposomes. All formulations differed in uptake and reduc-
tion of cell survival, depending on liposome composition.
Anionic Cardiolipin- and neutral 10% DOPE-liposomes
performed only equally well as free Magnevist solution.
DOTAP-liposomes were most effective in cell killing
under neutron irradiation in case of F98 cells, followed by
DOPC-DOPE- and folate-targeted liposomes. For LN229
cells, folate-liposomes were slightly more effective than
DOTAP-formulation, but reduced survival only by add-
itional 5% compared to the cationic liposomes.
The effect of the Gd-formulation alone on cellular sur-
vival is shown in Figure 10. Inactivation of tumor cells is
calculated by subtraction of total survival, based on the
irradiated medium control without drug, from theoret-
ical 100% survival. Thus, the resulting value takes only
the influence of the different liposomal Gd-formulations
into account, thereby neglecting the ‘basal neutron ir-
radiation’- effect provoked in all treatment groups. Al-
though the degree of inactivation differs slightly from
the effect on cell survival shown in Figure 6 - due to the
use of different control groups (irradiated versus non-
irradiated) - the general statement is the same: the
folate-, DOTAP- and DOPC-DOPE - liposomes are the
most effective Gd-formulations to inactivate both glioma
cell lines. For F98 cells, these liposomal formulations
lead to more than two-, three- and fivefold higher cellinactivation than the free Magnevist solution, respect-
ively. DOPC-DOPE liposomes inactivated here as much
as 65% of the cancer cells (significant results are marked
with asterisks, according to results from one-way
ANOVA and subsequent Tukey’s multiple comparison
of 15 groups, including drug-free liposomes of the differ-
ent lipid compositions, the analysis was performed sep-
arately for each cell line and for each fluence. F98 cells,
3.6 to 4.05 · 1012 n/cm2: R2 = 0.8582, residual sum of
squares: 1795, 37 degrees of freedom; LN229 cells, 2.4 to
2.7 · 1012 n/cm2: R2 = 0.7352, residual sum of squares:
772, 33 degrees of freedom). For LN229 cells, the effect
was lower, but still in the range of 23% inactivation
through the folate-targeted liposomes giving significantly
better results than the free Magnevist solution. With the
additional effect from the neutron irradiation, i.e. in com-
parison with non-irradiated control cells, the cellular sur-
vival can be reduced by 40% in case of LN229 cells via
administration of folate-targeted Gd-formulation and even
by 66% for F98 cells treated with Gd-containing DOTAP-
liposomes.
A likely explanation of high uptake and high effective-
ness of DOTAP-liposomes is the electrostatic interaction
between cationic liposome and anionic cell membrane,
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over, DOTAP liposomes seem to enter the cell by a dif-
ferent uptake pathway than DOPC-DOPE liposomes,
apparent in different uptake kinetics of the two formula-
tions. Accordingly, the uptake pathway also attributes to
cell killing effectiveness of the liposomal Magnevist in
addition to the total extent of liposome uptake. DOPC-
DOPE- and folate-targeted liposomes as well were more
effective than other liposome formulations delivering
higher amounts of Gd into cells, suggesting that differ-
ent uptake modalities of the formulations may be re-
sponsible for their different efficacy. In case of DOPC-
DOPE liposomes, the phenomenon can be ascribed to
facilitated escape of the liposome from the endosome
through conformational change of DOPE under acidic
conditions – a feat often exploited for gene delivery pur-
poses [18,26]. Once released into the cytosol, Gd-DTPA
may easily diffuse to the nucleus and reside in proximity
of the DNA instead of being trapped in lysosomes or
vacuoles. For folate-targeted liposomes, their uptake
pathway is still under investigation. It remains unclear
whether there is indeed an alternative pathway from cla-
thrin independent carriers or caveolin-mediated uptake
instead of lysosomal degradation, namely leading to the
endoplasmic reticulum in proximity to the nucleus -
from where high-linear energy transfer (LET) particles
would have better access to cellular DNA [16,27-29].
The results from cell irradiation experiments suggest
that the extracellular Gd-concentration that was com-
parable for all formulations does have very little influ-
ence on cell survival compared to the intracellular
concentration. Nevertheless, long range gamma rays
may in part be reabsorbed by Gd present in tumor tissue
and add to the overall dose (‘self-absorption’), but the ef-
fect is very small. Therefore, the accumulation of Gd in-
side the cell seems to be responsible for the major part
of DNA lesions leading to cell death. Correlation of
extracellular Gd-amount to cell survival was very poor,
but tendencies were distinguishable as higher Gd-
concentrations led to lower cell survival. In contrast, cel-
lular Gd-concentration plotted against cell survival
showed good correlation. However, discrepancy between
cellular Gd-amount and cell survival was obvious in case
of DOPC-DOPE and folate-liposomes, as described
above, suggesting that intracellular distribution of Gd
plays a prominent role in Gd-NCT and has to be taken
in account when planning NCT-treatment.
Interestingly, FR 1-positive LN229 and non-FR 1-
expressing F98 cells likewise took up folate-targeted li-
posomes. These findings are similar to Moret et al. 2013
[30] who found also a slightly higher uptake of folate-
bearing liposomes into FR 1-negative A549 cells com-
pared to non-targeted liposomes, whereas uptake of
folate-liposomes was enhanced approximately twofold inFR 1-positive KB cells. In our study, enhanced uptake of
targeted liposomes into LN229 was correspondingly 1.25
to 2-fold higher than for non-targeted formulations, with
the exception of cationic DOTAP-liposomes. In com-
parison to Lee and Low 1995 [31], who reported 45-fold
enhancement, this increase is relatively small. However,
one has to bear in mind that overall FR 1 expression on
gliomas or other brain tumors is usually very low, thus
leading to only slightly enhanced uptake in FR positive
cells [14]. Nevertheless, Saul et al. 2003 [13] have found
that even in brain tumors showing low FR 1 expression,
folate-targeted drug carriers could be very useful. After
the density of folate-moieties on the carrier surface had
been optimized for low-FR-1 expression C6 glioma cells,
they noted a considerable intracellular increase of the
loaded drug, doxorubicin, while uptake into non-FR 1
expressing E9 cells was still low. As a consequence, dif-
ferentiation between FR 1- positive tumor and FR 1-
negative surrounding normal cells may be achieved even
at low FR 1-receptor levels, thereby increasing effective-
ness of radiation enhancers under neutron capture
therapy.
Anionic liposomes containing Cardiolipin as marker
lipid were taken up to a lower extent than cationic or
folate-liposomes and led to smaller decrease in cell sur-
vival. As a lipid involved in apoptosis, we expected
higher effect on cell killing after uptake into F98 and
LN229 cells and maybe even higher uptake due to the
cell-innate character of the lipid. Unfortunately, the for-
mulation did not achieve satisfactory results under neu-
tron irradiation. For one part, low entrapment efficiency
and therefore lower transport of Gd into cells may be re-
sponsible for weak performance under neutron capture
conditions. On the other hand, the even lower delivery
of Gd by DOPC-DOPE liposomes did not diminish their
effectiveness for both cell lines. However, if cell debris
containing Cardiolipin as apoptosis marker is usually
taken up by glia cells and sorted into lysosomes, glioma
cells are likely to act likewise with liposomes containing
the same lipid. Gd in lysosomes may then be located too
far away from the cellular nucleus for efficient NCT.
These findings suggest that indeed the intracellular dis-
tribution of the Gd has higher impact on the success of
the therapy than the simple amount of Gd delivered into
target cells.
As was shown by Monte Carlo simulations, overall
dose on single-well level was mainly dictated by photons
derived from neutron capture events or from environment
of the thermal column. Doses varied from 4 and 6 Gy
(control group) to approximately 6 and 9 Gy (Magnevist 2
group) depending on Gd-content, for low and high neu-
tron fluence, respectively. The dose in 106 cells was calcu-
lated according to the up taken amount of gadolinium
delivered by the respective liposomes formulation, minus
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capture of nitrogen and the surrounding photons (from
control group). Consequently, the dose on the cellular
level was very small (0.001 to 0.3 Gy), but as observed
from correlation of dose to cell survival, of high import-
ance for the irradiation effect and differences between
liposome formulations.
Conclusions
Gadolinium-containing composite liposomes presented
here proved to be effective drug delivery agents for neutron
capture therapy in vitro. The application of different lipo-
somal formulations of FDA-approved MRI contrast agent
Magnevist led to significantly lower cell survival of glioma
cells compared to non-encapsulated Gd-DTPA for three
out of five new liposome compositions (DOTAP-, DOPC-
DOPE-, folate-liposomes), even without 157Gd enrichment.
For folate-targeted liposomes, specificity for low receptor
expression in brain cancer cells may be further optimized
via addressing the folate-density on liposome surface.
Furthermore, liposome composition and specific uptake
properties have high impact on irradiation effect, i.e. cell
killing under neutron irradiation, probably due to different
endocytic pathways and subsequent spatial orientation on
cellular level. The proximity of Gd-atoms to cellular DNA
was proven to be crucial for infliction of lethal damage. In-
vestigations of liposomal uptake mechanisms and intracel-
lular trafficking according to lipid composition are
therefore key points for further studies and optimization
of ‘Gd-loading’ of tumor cells before neutron irradiation.
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